echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > AstraZeneca China’s Western Headquarters was officially opened to facilitate the development of a healthy ecological integration in the Western Region

    AstraZeneca China’s Western Headquarters was officially opened to facilitate the development of a healthy ecological integration in the Western Region

    • Last Update: 2021-10-10
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Chengdu, September 28, 2021 /PRNewswire/ - Today, the "2021 Western Smart Medical Industry Summit" with the theme of "Ecological Integration, Winning the Future" was successfully held in Chengdu High-tech Zone, Sichuan Province
    .


    As one of the organizers of the summit, AstraZeneca, the world's leading multinational pharmaceutical company, announced at the summit the official opening of AstraZeneca's western China headquarters in the Chengdu High-tech Zone


    AstraZeneca China West Headquarters Building

    Build a value link platform to help build a healthy ecosystem in the western region

    The "2021 Western Smart Medical Industry Summit" aims to integrate multiple platforms such as governments, enterprises, academic institutions, research institutions, capital, and hospitals to aggregate resources and achieve the same frequency resonance and integrated development of the western health ecosystem
    .


    More than 50 senior executives from well-known pharmaceutical companies at home and abroad, TOP-level clinical achievement transformation institutions, leading western enterprises, and top medical industry investors attended and participated in roundtable forums, summit dialogues, sub-forums and other links.


    On September 28, the "2021 Western Smart Medical Industry Summit" was held in Chengdu

    As the venue of this summit, it is also a node city of the "One Belt One Road" strategy and the most dynamic capital in western China.
    Chengdu is rich in clinical medical resources and human resources, and has a good biomedical innovation capability and industrial development foundation.
    In recent years, we have been committed to "ecological integration" from the industrial chain, element chain, supply chain, value chain and innovation chain in the medical field, and the efforts of all parties to promote the formation of the bio-industry ecosystem
    .


    As the main front for the development of the biopharmaceutical industry, Chengdu High-tech Zone has initially formed key industrial clusters such as modern Chinese medicine, chemical medicine, biological preparations, and medical equipment, and has attracted more than 3,000 pharmaceutical companies to settle in


    Wang Lei, Executive Vice President of AstraZeneca Global and President of International Business and China, said: "Under the impetus of the country's'innovation-driven development' strategy, the development of China's pharmaceutical industry is entering a new era.
    The 2021 Western Smart Medical Industry Summit can be described as the right time.

    In recent years, the governments of Chengdu and Chengdu High-tech Zone have provided strong support to the biopharmaceutical industry, continue to provide good element guarantees and supporting support for the biopharmaceutical industry, continuously optimize the business environment, and work together with AstraZeneca to build a multi-party An exchange and value link platform that integrates innovative elements such as government, enterprises, technology, capital, and clinics, promotes cross-industry cooperation, promotes the transformation of substantive results, and effectively empowers the innovation and upgrading of the western health industry
    .


    "

    Wang Lei, Executive Vice President of AstraZeneca Global and President of International Business and China, delivered a keynote speech at the summit

    The summit also brought together important forces such as government leaders, industry leaders, pharmaceutical giants, new entrepreneurs, etc.


    , in the sub-forums to discuss new industrial opportunities under local innovation and medical insurance reform, integration of Chinese and Western medicine and innovative development, Internet hospitals and other industries.


    At the sub-forum of "New Development and New Ideas for Internet Hospitals", AstraZeneca China General Manager Lai Minglong expressed his full optimism about the development of "Internet + Medical" and was full of expectations
    .


    "Digital medical care is a very important trend.


    Lai Minglong, General Manager of AstraZeneca China, gave an opening speech at the sub-forum of "New Development and New Ideas for Internet Hospitals"

    Take root in the west and deepen China's commitment

    AstraZeneca’s Western China Headquarters, which was grandly unveiled at this summit, is located in the Frontier Medical Center of Chengdu High-tech Zone.
    Company operations management, sales market and other affairs in ten provinces and cities including Shaanxi, Hubei, Xinjiang, Gansu, Guizhou, Qinghai, Ningxia, Tibet, and integrated AstraZeneca's innovative medicines and innovative diagnosis and treatment solutions for the whole course of disease management Bring it to the west to further benefit patients in the west
    .


    With the opening of the Western Headquarters, the Chengdu International Life Science Innovation Park and the Modern Innovation Center for Integrated Traditional Chinese and Western Medicine have also settled in Chengdu High-tech Zone simultaneously, helping Chengdu to build an international western health industry ecosystem


    Chengdu International Life Science Innovation Park made its debut at this summit.
    The park is a life science innovation incubation platform jointly built by AstraZeneca, Chengdu Municipal Government and Chengdu High-tech Zone, and is committed to creating an open, innovative and global life sciences in the west.
    Scientific innovation ecosystem
    .


    Relying on an innovative government-enterprise cooperation model, the Innovation Park will build a characteristic ecosystem of Chengdu's pharmaceutical industry, focusing on new drug R&D, high-end equipment, smart medical and other fields, and providing project landing, innovation incubation, business acceleration, industrial investment and international One-stop empowerment platform such as chemical cooperation


    At the same time, the park was also designated by the Chengdu Medical and Health Industry Alliance as the "Chengdu Medical and Health Industry Ecosphere Alliance Activity Base".
    As the core activity space of the alliance's medical innovation, a licensing ceremony was held at the summit
    .

    The "Chengdu Modern Innovation Center for Integrated Traditional Chinese and Western Medicine" was officially inaugurated today, and it has joined hands with Jiaruikang, Sannuo Biotechnology, Hanwei Technology, Dajing Traditional Chinese Medicine, Omron, Xinyun Hengan, Xiangsheng Medical, Airdoc Beijing Yingtong, Chengyi Family , Sunwo Medical's 10 partners held a signing ceremony at the summit
    .


    Through the innovative cooperation model of "experts, industry, co-creation, and results", AstraZeneca will unite partners in politics, industry, academia, research, medicine, and investment, and combine local industrial advantages to incubate "integrated Chinese and Western medicine.
    " +The new model of "smart medical care" accelerates the creation of innovative integrated diagnosis and treatment solutions with Chinese medicine elements, and accelerates the promotion and application of it to help the intelligent development of integrated Chinese and Western medicine
    .

    AstraZeneca CICC Medical Industry Fund also announced that it intends to start cooperation with the investment platform of Chengdu High-tech Zone
    .
    The two parties will make full use of AstraZeneca's resources in the global medical and health field, and CICC's profound investment management and capital operation experience.
    Through the cooperation of government, industry and investment, the two parties will enhance the effectiveness of investment in the medical and health industry in Chengdu, and jointly accelerate Innovative development of Chengdu's medical and health industry
    .

    Wang Lei, Executive Vice President of AstraZeneca Global and President of International Business and China, said: “As the engine city of the Western Development, Chengdu plays a role as a window to the surrounding areas and has an important influence
    .
    AstraZeneca’s China West Headquarters is rooted in Chengdu.
    This is an important step towards going deep into the west
    .
    In the future, AstraZeneca will continue to increase investment, unite government, industry, academia, research, medicine, and investment to explore more innovative cooperation models and promote innovation in the western health industry.
    Development to better meet the growing health needs of local patients
    .
    "

    On the day of the summit, AstraZeneca also signed a cooperation agreement with West China Hospital of Sichuan University to jointly assist in the research and development of innovative drugs and serve the vast number of patients in China and around the world; and signed the " "Smart Community Chronic Disease Management Strategic Cooperation Memorandum", dedicated to the comprehensive health management of chronic disease patients by primary medical institutions
    .
    In order to better promote the implementation of "Internet + Medical", the Chengdu Huiyi World Internet Hospital was also unveiled on the same day, and a number of partners were signed to further serve a wider range of patients, and continue to explore the cooperation model of online and offline integration and co-construction
    .
    In addition, AstraZeneca Pharmaceuticals (Chengdu) Co.
    , Ltd.
    was officially inaugurated on the same day.
    Since then, AstraZeneca's innovative imported products will be officially sold from Chengdu to all parts of the country
    .

    China's regional headquarters strategy is AstraZeneca's future-oriented development plan proposed in 2019 in order to actively respond to the general trend of coordinated development of China's regional economy
    .
    Since the beginning of this year, AstraZeneca has opened its northern headquarters in Beijing Economic and Technological Development Zone and its eastern headquarters in Gongshu District, Hangzhou.
    It is expected that all five regional headquarters will be launched within this year, forming a mutual promotion with the Shanghai China headquarters.
    , Linkage Development’s new strategic layout in China, fulfilling AstraZeneca’s unchanging promise of “in China, for China”
    .

    About AstraZeneca

    AstraZeneca (LSE/STO/Nasdaq: AZN) is a science-first global biopharmaceutical company, focusing on the research and development, production and marketing of prescription drugs, focusing on tumors, cardiovascular, kidney and metabolism, breathing and immunity.
    Major disease areas
    .
    AstraZeneca's global headquarters is located in Cambridge, England, with operations in more than 100 countries around the world, and innovative drugs benefit millions of patients worldwide
    .
    For more information, please visit
    .

    About AstraZeneca China

    Since entering China in 1993, AstraZeneca has insisted on the supremacy of science and innovation to meet China's growing health needs and realize the grand vision of "pioneering and innovating, benefiting patients, and becoming China's most trusted medical partner"
    .
    AstraZeneca's China headquarters is located in Shanghai, and has established regional headquarters in Beijing, Guangzhou, Wuxi, Hangzhou, and Chengdu
    .
    It has nearly 20,000 employees nationwide .
    The company has invested in production bases in Wuxi and Taizhou, Jiangsu, and established a China logistics center in Wuxi
    .
    In China, AstraZeneca's business focus is mainly on the treatment areas most urgently needed by Chinese patients, including respiratory, cardiovascular, metabolism, tumor, digestion, and kidney diseases
    .
    In 2017, the China Health Internet of Things Innovation Center was launched in Wuxi, aiming to explore innovative health Internet of Things diagnosis and treatment integrated whole-course management solutions
    .
    In the same year, AstraZeneca and SDIC Innovations jointly established Dizhe (Jiangsu) Pharmaceutical Co.
    , Ltd.
    to accelerate the pace of local new drug research and development
    .
    In 2019, AstraZeneca announced that it will cooperate with Wuxi to build the Wuxi International Life Science Innovation Park, bringing together global wisdom and benefiting Chinese patients
    .
    In the same year, AstraZeneca announced the establishment of a global R&D China center in Shanghai and the establishment of a global medical industry fund
    .
    In 2020, AstraZeneca announced its support for the "Internet Hospital" project
    .

    Source: AstraZeneca

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.